Liyan Qiao

Dr. Liyan Qiao


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
BSBingxin Shi
Bingxin Shi
MZMangsuo Zhao
Mangsuo Zhao
TGTongchao Geng
Tongchao Geng
LQLiyan Qiao
Liyan Qiao
YZYapeng Zhao
Yapeng Zhao
XZXiuli Zhao
Xiuli Zhao

1 September 2021 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
BSBingxin Shi
Bingxin Shi
MZMangsuo Zhao
Mangsuo Zhao
LQLiyan Qiao
Liyan Qiao
FHFangjie Huang
Fangjie Huang
SZShimei Zhou
Shimei Zhou
NWNing Wang
Ning Wang

1 March 2015 in Journal of Neurorestoratology
Verified
Journal Article
Open access
PDF file
LQLiyan Qiao
Liyan Qiao
JLJun Lu
Jun Lu
HHHongyun Huang
Hongyun Huang
Stroke is the second most common single cause of death worldwide, with over five million deaths per year globally. So far, conventional therapy has failed to restore neurological function poststroke. Neurorestorative strategy has provided therapeutic benefit for the treatment of stroke. This review outlines the clinical advances, in which cell-based neurorestorative strategies offer the broadest range of potential treatments for stroke.

7 September 2020 in International Journal of Neuroscience
Verified
Journal Article
Closed access
MZMangsuo Zhao
Mangsuo Zhao
MZMingjie Zhang
Mingjie Zhang
SZShimei Zhou
Shimei Zhou
BSBingxin Shi
Bingxin Shi
WYWei Yan
Wei Yan
LQLiyan Qiao
Liyan Qiao
Only five patients diagnosed with transverse myelitis (TM) associated with primary biliary cirrhosis (PBC) have been reported in the literature to date. We report two additional patients with TM as...

28 July 2025 in JMIR Formative Research
Verified
Journal Article
Open access
XLXiaojun Lai
Xiaojun Lai
LQLiyan Qiao
Liyan Qiao
PRPei-Luen Patrick Rau
Pei-Luen Patrick Rau
YLYankuan Liu
Yankuan Liu
Background: Cerebral small vessel disease (CSVD) significantly impacts motor functions, particularly gait dynamics. However, its analysis often lacks the integration of comprehensive tools that capture the multifaceted nature of gait disturbances. Traditional methods may not fully address the complexity of CSVD’s impact on gait, underscoring the need for a detailed exploration of gait characteristics through advanced technological means. Objective: This study aims to identify the distinct gait patterns and postural adaptations present in patients with CSVD compared to a healthy older population, using an integrative analysis combining sensor and video data to provide a holistic understanding of gait dynamics in CSVD. Methods: This study involved 90 participants older than 50 years (mean age 68.85, SD 9.74 years; 47 males and 43 females), with 24 categorized as normal controls (mean age 66.42, SD 7.51 years) and 66 diagnosed with CSVD (mean age 69.74, SD 10.37 years). Participants performed three walking tasks: normal walking, dual-task walking (with concurrent mental arithmetic), and fast walking. Gait parameters were collected through video data for image posture parameters using the OpenPose BODY_25 key point model, and the “Pocket Gait Test” smartphone app for sensor-based parameters sampled at approximately 40 Hz. Data analysis included 5 sensor-based parameters (step frequency, root mean square (RMS), step variability, step regularity, and step symmetry) and 6 key video-based parameters (including knee angle, ankle angle, elbow angle, body trunk angles, and head posture). Results: Among the 29 participants with complete sensor and video data (10 normal controls and 19 patients with CSVD), significant differences were observed in step regularity (normal walking: mean 0.76, SD 0.09 vs mean 0.61, SD 0.25; P<.003 and dual-task: mean 0.74, SD 0.13 vs mean 0.57 SD 0.24; P<.005), RMS (normal walking: mean 1.64, SD 0.45 vs mean 1.43, SD 0.42; P<.006), and forward head posture angles (head-to-body angle during normal walking: mean 132.96, SD 7.78 vs mean 128.07, SD 7.99; P<.02 and head-to-ground angle: mean 134.11, SD 8.28 vs mean 128.40, SD 9.75; P<.008) between the CSVD and control groups. The CSVD group exhibited a more pronounced forward head posture across all walking tasks, with the greatest difference observed during dual-task walking (head-to-ground angle: mean 134.43, SD 8.29 vs mean 125.02, SD 8.42; P<.02). Conclusions: The study provides compelling evidence of distinct gait disturbances in patients with CSVD, characterized by reduced step regularity (15%‐23% lower than controls), altered acceleration patterns, and significant postural adaptations, particularly forward head positioning (4°‐7° more pronounced than controls). These quantifiable differences, detectable through accessible smartphone and video technology, offer potential biomarkers for early CSVD detection and monitoring. The integration of sensor and video analysis provides a more comprehensive assessment approach that could be implemented in both clinical and home settings for longitudinal monitoring of disease progression and rehabilitation outcomes.

7 October 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
BYBin Yang
Bin Yang
JWJing Wang
Jing Wang
XZXiuli Zhao
Xiuli Zhao
CJChuya Jing
Chuya Jing
JYJian Yin
Jian Yin
LQLiyan Qiao
Liyan Qiao
Introduction: Eculizumab, an antibody that inhibits the complement system, and the immunosuppressant Tacrolimus are both authorized for treating patients with generalized myasthenia gravis (GMG). This study seeks to evaluate and compare the clinical effectiveness of Eculizumab with or with not Tacrolimus in the treatment of generalized myasthenia gravis. Methods: A retrospective study was performed involving 95 patients with GMG treated with Eculizumab at three hospitals in China. Among them, 80 patients were included in the analysis: 57 received Eculizumab alone, while 23 were treated with a combination of Eculizumab and Tacrolimus. The main outcome assessed was the percentage of GMG patients who reached Minimal Symptom Expression (MSE). Secondary outcomes included changes in MG-Activities of Daily Living (MG-ADL) scale, Quantitative Myasthenia Gravis (QMG) score, CH50 concentration, and doses of pyridostigmine and prednisolone. Additionally, the safety profiles of both treatment groups were examined. Results: In the main outcome, a higher proportion of patients reached MSE status when treated with a combination of Eculizumab and Tacrolimus compared to Eculizumab alone (Eculizumab: 29 patients, 50.9% vs Eculizumab and Tacrolimus: 18 patients, 78.3%; p0.05). The decrease in complement CH50 concentration is accompanied by a decrease in QMG and MG-ADL scores, indicating that Eculizumab treats GMG through the mechanism of complement system. In terms of security, hyperuricemia was more commonly associated with the combination therapy of Eculizumab and Tacrolimus than with Eculizumab alone. Conclusion: Our research indicates that Eculizumab can effectively reduce disability in GMG patients by inhibiting complement system activation under real-world clinical conditions in China. We observed a correlative link between Eculizumab and Tacrolimus combination treatment and an increased probability of achieving MSE status, in comparison with Eculizumab monotherapy. However, combination therapy is associated with a higher risk of elevated serum uric acid among GMG patients, which necessitates regular close monitoring of renal function.